FTC Approves Final Order Imposing Conditions on Boston Scientific Corp.’s Acquisition of BTG plc

Under the final order, Boston Scientific is required to divest to Varian Medical Systems its DEB business, as well as its bland bead product line.

Metadata
Provider: 
FTCFTC
URL: 
https://www.ftc.gov/news-events/press-releases/2019/09/ftc-approves-final-order-imposing-conditions-boston-scientifichttps://www.ftc.gov/news-events/press-releases/2019/09/ftc-approves-final-order-imposing-conditions-boston-scientific
Retrieved on: 
Thursday, September 19, 2019
Information
Tags: 
Corporate finance, Divestment, Investment, Outsourcing
Summary
Key Points: 
  • Under the final order, Boston Scientific is required to divest to Varian Medical Systems its DEB business, as well as its bland bead product line.
  • According to the FTC, Boston Scientifics bland bead business must be divested with its DEB business to ensure the divestitures effectiveness.
  • The CNMC closed its investigation and cleared the transaction, subject to Boston Scientific fulfilling the terms contained in the FTCs consent order.
  • Like the FTC on Facebook, follow us on Twitter, read our blogs, and subscribe to press releases for the latest FTC news and resources.
Copyright: 
2019 FTC. All Rights Reserved.